Tim Miller, Forge Biologics CEO (Forge)

Forge Bi­o­log­ics bags $120M round as it looks to scale AAV man­u­fac­tur­ing for Krabbe dis­ease treat­ment

In less than a year, Forge Bi­o­log­ics has grown its staff size from just four em­ploy­ees to more than 75, a sure sign of rapid growth from the Chris Garabe­di­an-launched start up. Here’s an­oth­er sign: the $120 mil­lion Se­ries B fi­nanc­ing round the com­pa­ny just an­nounced.

The gene ther­a­py CD­MO se­cured fund­ing from RA Cap­i­tal Man­age­ment, and par­tic­i­pa­tion from Per­cep­tive Ad­vi­sors, Sur­vey­or Cap­i­tal, Oc­ta­gon Cap­i­tal and Mar­shall Wace.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.